Insider Selling: Nkarta, Inc. (NASDAQ:NKTX) Insider Sells 3,396 Shares of Stock

Nkarta, Inc. (NASDAQ:NKTX) insider Alicia J. Hager sold 3,396 shares of the company’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $8.00, for a total transaction of $27,168.00. Following the completion of the sale, the insider now directly owns 103,819 shares in the company, valued at $830,552. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Nkarta Stock Performance

Shares of Nkarta stock opened at $6.21 on Friday. Nkarta, Inc. has a twelve month low of $1.28 and a twelve month high of $16.24. The business has a 50-day moving average price of $6.26 and a 200 day moving average price of $8.45.

Nkarta (NASDAQ:NKTX) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.02). As a group, equities analysts expect that Nkarta, Inc. will post -2.27 EPS for the current fiscal year.

Hedge Funds Weigh In On Nkarta

A number of large investors have recently added to or reduced their stakes in NKTX. SG Americas Securities LLC acquired a new position in shares of Nkarta during the 4th quarter worth about $72,000. Bleakley Financial Group LLC purchased a new stake in Nkarta during the 4th quarter worth approximately $70,000. Simplicity Solutions LLC acquired a new position in shares of Nkarta during the fourth quarter valued at approximately $70,000. Bourgeon Capital Management LLC purchased a new position in shares of Nkarta in the fourth quarter valued at approximately $30,000. Finally, abrdn plc acquired a new stake in shares of Nkarta in the fourth quarter worth approximately $191,000. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently commented on NKTX shares. Needham & Company LLC restated a “buy” rating and issued a $13.00 target price on shares of Nkarta in a research note on Friday, June 28th. Canaccord Genuity Group lowered their price objective on Nkarta from $16.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $23.00 target price on shares of Nkarta in a report on Thursday, June 27th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Nkarta presently has a consensus rating of “Buy” and a consensus target price of $17.83.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.